William D. Baird III - 11 Nov 2021 Form 4 Insider Report for bluebird bio, Inc. (BLUE)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
17 Nov 2021, 07:55:59 UTC
Prior SEC filing
18 Oct 2021
Next SEC filing
11 Jan 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Helen Fu, Attorney-in-Fact

Key filing fact

William D. Baird III filed Form 4 for bluebird bio, Inc. (BLUE) on 17 Nov 2021.

Key facts

  • This page summarizes William D. Baird III's Form 4 filing for bluebird bio, Inc. (BLUE).
  • 8 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 17 Nov 2021, 07:55.

Change

  • Previous filing in this sequence was filed on 18 Oct 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
+7,384
Change %
+92%
Price
$0.000000
Shares after
15,413
Date
11 Nov 2021
Ownership
Direct
Footnotes
F1, F2, F3
BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
+7,384
Change %
+48%
Price
$0.000000
Shares after
22,797
Date
11 Nov 2021
Ownership
Direct
Footnotes
F2, F3, F4
BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
0
Change %
0%
Price
$0.000000*
Shares after
22,797
Date
11 Nov 2021
Ownership
Direct
Footnotes
F2, F3, F5
BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
0
Change %
0%
Price
$0.000000*
Shares after
22,797
Date
11 Nov 2021
Ownership
Direct
Footnotes
F2, F3, F6
BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
0
Change %
0%
Price
$0.000000*
Shares after
22,797
Date
11 Nov 2021
Ownership
Direct
Footnotes
F2, F3, F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLUE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-60,000
Change %
-50%
Price
$0.000000
Shares after
59,072
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
59,072
Exercise price
$78.03
Footnotes
F8
BLUE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-20,000
Change %
-50%
Price
$0.000000
Shares after
19,690
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
19,690
Exercise price
$36.78
Footnotes
F9
BLUE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-25,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0
Exercise price
$0.000000
Footnotes
F10
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on March 1, 2019 and vests over a four-year period at a rate of 25% on 2/11/2020, 25% on 2/11/2021, 25% on 2/11/2022, and 25% on 2/11/2023.

Footnote F2

bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP").

Footnote F3

bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP.

Footnote F4

Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on March 2, 2020 and vests over a four-year period at the rate of 25% on 01/04/2021, 25% on 01/04/2022, 25% on 01/04/2023, and 25% on 01/04/2024.

Footnote F5

Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on February 16, 2021 and vests over a four-year period at a rate of 25% on 01/04/2022, 25% on 01/04/2023, 25% on 01/04/2024, and 25% on 01/04/2025.

Footnote F6

Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on August 2, 2021 and vests over a two-year period at the rate of 40% on August 2, 2022 and 60% on August 2, 2023.

Footnote F7

Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on August 2, 2021 and vests upon the satisfaction of certain performance criteria.

Footnote F8

Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 1, 2019 and vests over a four-year period, at a rate of 25% on 02/11/2020 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.

Footnote F9

Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 2, 2020 and vests over a four-year period, at a rate of 25% on 01/04/2021 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.

Footnote F10

Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 16, 2021 and vests over a four-year period, at a rate of 25% on 01/04/2022 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .